MDXH
MDxHealth SA
NASDAQ · Healthcare · Medical - Diagnostics & Research · BE
$0.63
−6.21%Year over year
Reported trailing growth
- Revenue
- +9.7%
- EBITDA
- -43.7%
- EBIT
- -32.1%
- EPS
- +29.8%
- Free cash flow
- +49.9%
- Operating cash flow
- +47.1%
Forward estimates
Based on analyst estimates
- Revenue
- -27.3%
- EBITDA
- +237.0%
- EPS
- +74.5%
Three-year CAGR
- Revenue
- +42.8%
- EBITDA
- +36.4%
- EBIT
- +37.7%
- Net income
- +12.0%
- EPS
- +14.1%
- Free cash flow
- +44.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026